Humacyte Stock is Pure Play on Regenerative Medicine
Over the last couple of years, more than half of all companies that went public came through the back door via mergers with special purpose acquisition companies (SPACs). We all know how that has turned out – pretty much what we warned about several years ago in a piece titled How SPACs Reward Everyone Except […]